Swiss National Bank Has $4.67 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN)

Swiss National Bank boosted its stake in shares of Arvinas, Inc. (NASDAQ:ARVN) by 1.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 70,700 shares of the company’s stock after buying an additional 800 shares during the period. Swiss National Bank owned about 0.14% of Arvinas worth $4,673,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the company. Victory Capital Management Inc. increased its holdings in shares of Arvinas by 5.0% in the 1st quarter. Victory Capital Management Inc. now owns 6,192 shares of the company’s stock valued at $409,000 after purchasing an additional 296 shares during the period. US Bancorp DE increased its holdings in shares of Arvinas by 253.7% in the 1st quarter. US Bancorp DE now owns 520 shares of the company’s stock valued at $35,000 after purchasing an additional 373 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in shares of Arvinas by 3.1% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 13,252 shares of the company’s stock valued at $1,125,000 after purchasing an additional 400 shares during the period. Alliancebernstein L.P. increased its holdings in shares of Arvinas by 1.1% in the 1st quarter. Alliancebernstein L.P. now owns 47,200 shares of the company’s stock valued at $3,120,000 after purchasing an additional 500 shares during the period. Finally, IndexIQ Advisors LLC increased its holdings in shares of Arvinas by 11.5% in the 4th quarter. IndexIQ Advisors LLC now owns 5,197 shares of the company’s stock valued at $441,000 after purchasing an additional 536 shares during the period. Institutional investors own 88.13% of the company’s stock.

In other Arvinas news, insider Ian Taylor sold 25,000 shares of the stock in a transaction on Monday, April 5th. The stock was sold at an average price of $66.81, for a total transaction of $1,670,250.00. Following the completion of the transaction, the insider now directly owns 103,645 shares in the company, valued at $6,924,522.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.99% of the company’s stock.

A number of equities analysts recently commented on ARVN shares. Truist started coverage on Arvinas in a report on Wednesday, April 21st. They issued a “buy” rating and a $150.00 price objective on the stock. Zacks Investment Research upgraded Arvinas from a “sell” rating to a “hold” rating in a report on Friday, May 7th. BMO Capital Markets started coverage on Arvinas in a report on Wednesday, March 31st. They issued an “outperform” rating and a $101.00 price objective on the stock. Truist Securities assumed coverage on Arvinas in a report on Wednesday, April 21st. They issued a “buy” rating and a $150.00 price objective on the stock. Finally, Northern Trust Capital Markets assumed coverage on Arvinas in a research report on Wednesday, April 21st. They set a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $117.00.

Shares of ARVN stock opened at $82.78 on Friday. The company has a market capitalization of $4.06 billion, a PE ratio of -25.31 and a beta of 2.01. Arvinas, Inc. has a one year low of $19.68 and a one year high of $92.77. The business has a fifty day moving average price of $66.98.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings data on Monday, May 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.01). Arvinas had a negative return on equity of 33.38% and a negative net margin of 656.61%. Analysts predict that Arvinas, Inc. will post -3.45 EPS for the current fiscal year.

Arvinas Profile

Arvinas, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

Featured Story: Technical Analysis of Stocks, How Can It Help

Institutional Ownership by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.